Cargando…
Long‐term safety and efficacy of N8‐GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5
BACKGROUND: N8‐GP (turoctocog alfa pegol; Esperoct(®), Novo Nordisk A/S, Bagsvaerd, Denmark) is a glycoPEGylated, extended half‐life human recombinant factor VIII (FVIII). OBJECTIVE: Here, we report end‐of‐trial safety and efficacy results from the completed N8‐GP pathfinder5 trial. METHODS: pathfin...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540298/ https://www.ncbi.nlm.nih.gov/pubmed/32940955 http://dx.doi.org/10.1111/jth.15036 |